title: [Profile of bacterial resistance in pediatric urinary tract infections in 2014].
abstract: In pediatric units, bacteria-producing extended-spectrum-betalactamase (ESBL) have an increasing prevalence among bacteria causing febrile urinary tract infections (UTIs). The purpose of this study was to evaluate the epidemiology of bacteria resistance patterns observed in UTIs, in order to assess the current antibiotic treatment protocols. This study is based upon a single-center retrospective chart review of the cytobacteriological urine cultures performed in UTIs between 1 January and 31 December 2014, in the medical pediatric unit of the Caen University Hospital. Out of the total of 219 cases of UTI, 26.9% were recurrences of UTI, 18.3% were infections in infants less than 3 months old, 21% of the patients suffered from underlying uropathy, and 16.4% of the patients had recently been exposed to antibiotics. In 80.3% of the cases, Escherichia coli was found, while Enterococcus faecalis was found in 5.6%. The antibiograms proved that 33.5% of the bacteria were sensitive. Half of E. coli were resistant to ampicillin, 4.9% to cefixime, 4.9% to ceftriaxone, 1.1% to gentamicin, and 27.8% to trimethoprim-sulfamethoxazole. Nine E. coli and one Enterobacter cloacae produced ESBL, accounting for 4.6% of the UTIs. We did not find any bacteria-producing high-level cephalosporinase. Cefixime resistance was statistically linked to ongoing antibiotic treatment (OR=5.98; 95% CI [1.44; 24.91], P=0.014) and underlying uropathy (OR=6.24; 95% CI [1.47; 26.42], P=0.013). Ceftriaxone resistance was statistically related to ongoing antibiotic treatment (OR=6.93; 95% CI [1.45; 33.13], P=0.015). These results argue in favor of maintaining intravenous ceftriaxone for probabilistic ambulatory treatment. However, in case of hospitalization, cefotaxime can replace ceftriaxone, due to its lower ecological impact. Moreover, it is necessary to continue monitoring bacterial resistance and regularly review our treatment protocols.
authors.affiliation: Service de pédiatrie médicale, CHU de Caen, avenue Côte-de-Nacre, 14033 Caen, France. Electronic address: agathe.flammang@gmail.com.
authors.forename: A
authors.initials: A
authors.lastname: Flammang
authors.affiliation: Département de biostatistiques et de recherche clinique, CHU de Caen, avenue Georges-Clémenceau, 14033 Caen, France.
authors.forename: R
authors.initials: R
authors.lastname: Morello
authors.affiliation: Laboratoire de microbiologie, CHU de Caen, avenue Côte-de-Nacre, 14033 Caen, France.
authors.forename: M
authors.initials: M
authors.lastname: Vergnaud
authors.affiliation: Service de pédiatrie médicale, CHU de Caen, avenue Côte-de-Nacre, 14033 Caen, France.
authors.forename: J
authors.initials: J
authors.lastname: Brouard
authors.affiliation: Service de pédiatrie médicale, CHU de Caen, avenue Côte-de-Nacre, 14033 Caen, France.
authors.forename: P
authors.initials: P
authors.lastname: Eckart
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000188:drug therapy* / Q000453:epidemiology / Q000382:microbiology*; D003430:Cross-Sectional Studies; D024881:Drug Resistance, Bacterial; D013293:Enterococcus faecalis; D004927:Escherichia coli Infections / Q000188:drug therapy / Q000453:epidemiology / Q000382:microbiology; D016908:Gram-Positive Bacterial Infections / Q000188:drug therapy / Q000453:epidemiology / Q000382:microbiology; D006801:Humans; D007223:Infant; D008826:Microbial Sensitivity Tests; D011704:Pyelonephritis / Q000188:drug therapy* / Q000453:epidemiology / Q000382:microbiology*; D012008:Recurrence; D012189:Retrospective Studies; D012307:Risk Factors
chemical_list: D000900:Anti-Bacterial Agents